Evidence map›Paper›PMID 19903733›Full record

ArticleBrain : a journal of neurology2010

Effects of baclofen on motor units paralysed by chronic cervical spinal cord injury.

Christine K Thomas, Charlotte K Häger-Ross, Cliff S Klein

Abstract readComparative Study
In one paragraph

Article in Brain : a journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  2. Relationship Between Spinal Reflexes and Spastic Movement Disorders.Physical medicine and rehabilitation clinics of North America · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Efficacy and safety of tolperisone versus baclofen among Chinese patients with spasticity associated with spinal cord injury: a non-randomized retrospective study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  12. Article
  13. Article
  14. Imbalanced Corticospinal and Reticulospinal Contributions to Spasticity in Humans with Spinal Cord Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christine K ThomasThe Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, 1095 NW 14 Terrace, R48, Miami, FL 33136-2104, USA. cthomas@miami.edu
Charlotte K Häger-Ross
Cliff S Klein

Funding

MUSCLE FUNCTION IN HUMAN CERVICAL SPINAL CORD INJURYR01NS030226 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI THOMAS, CHRISTINE K · 1994 to 2010
$3.0M
Muscle Function in Human Cervical Spinal Cord InjuryR56NS030226 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI THOMAS, CHRISTINE K · 2007 to 2007
$396k
NINDS NIH HHS NS-30226
6 · The paper itself

Abstract

Baclofen, a gamma-aminobutyric acid receptor(B) agonist, is used to reduce symptoms of spasticity (hyperreflexia, increases in muscle tone, involuntary muscle activity), but the long-term effects of sustained baclofen use on skeletal muscle properties are unclear. The aim of our study was to evaluate whether baclofen use and paralysis due to cervical spinal cord injury change the contractile properties of human thenar motor units more than paralysis alone. Evoked electromyographic activity and force were recorded in response to intraneural stimulation of single motor axons to thenar motor units. Data from three groups of motor units were compared: 23 paralysed units from spinal cord injured subjects who take baclofen and have done so for a median of 7 years, 25 paralysed units from spinal cord injured subjects who do not take baclofen (median: 10 years) and 45 units from uninjured control subjects. Paralysed motor unit properties were independent of injury duration and level. With paralysis and baclofen, the median motor unit tetanic forces were significantly weaker, twitch half-relaxation times longer and half maximal forces reached at lower frequencies than for units from uninjured subjects. The median values for these same parameters after paralysis alone were comparable to control data. Axon conduction velocities differed across groups and were slowest for paralysed units from subjects who were not taking baclofen and fastest for units from the uninjured. Greater motor unit weakness with long-term baclofen use and paralysis will make the whole muscle weaker and more fatigable. Significantly more paralysed motor units need to be excited during patterned electrical stimulation to produce any given force over time. The short-term benefits of baclofen on spasticity (e.g. management of muscle spasms that may otherwise hinder movement or social interactions) therefore have to be considered in relation to its possible long-term effects on muscle rehabilitation. Restoring the strength and speed of paralysed muscles to pre-injury levels may require more extensive therapy when baclofen is used chronically.

Indexed as

AdultBaclofenCervical VertebraeChronic DiseaseElectric StimulationFemaleHumansMaleMiddle AgedMotor NeuronsMuscle Fibers, SkeletalParalysisSpinal Cord InjuriesYoung AdultBaclofen

Identifiers

PMID19903733
PMCPMC2857957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.